AbbVie Inc. stock (US00287Y1091): FDA approval for DECNUPAZ and major Norges Bank stake highlight oncology momentum

AbbVie, listed on the New York Stock Exchange under the ticker ABBV, drew fresh investor attention in the United States this week after the U.S. Food and Drug Administration approved DECNUPAZ for a rare blood cancer and Norges Bank reported a multibillion?dollar equity position in the company, signaling both regulatory and institutional support for the Chicago?area biopharma group.AbbVie press release as of 05/27/2026

According to AbbVie, the FDA on 05/27/2026 granted approval for DECNUPAZ (pivekimab sunirine?pvzy) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, an ultra?rare and aggressive hematologic malignancy with limited existing options.FinanzNachrichten/PR Newswire as of 05/27/2026 The company highlighted that DECNUPAZ is the first and only antibody?drug conjugate targeting CD123 to be approved for BPDCN, opening a new oncology niche in its U.S. product portfolio.

The stock traded at USD 165.40 on 05/30/2026 on the NYSE, with a modest gain of around 1% for the week, according to exchange data.NYSE as of 05/30/2026 In Germany, AbbVie was quoted at about EUR 153.20 on Tradegate on 05/30/2026, underlining continued demand from European retail investors alongside the U.S. listing.

In a separate development relevant to U.S. markets, Norges Bank disclosed that it acquired 25,668,761 AbbVie shares during the fourth quarter, valued at approximately USD 5.87 billion and representing about 1.45% of the company’s outstanding stock, according to a recent SEC filing summarized by MarketBeat.MarketBeat as of 05/30/2026 The position makes the U.S. pharmaceutical group the 19th?largest holding for Norway’s central bank, underscoring significant long?term institutional interest in AbbVie’s equity story.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

AbbVie Inc.: core business model

AbbVie focuses on discovering and commercializing branded prescription medicines, with sales concentrated in immunology, oncology, neuroscience and aesthetics where patent?protected therapies and specialty biologics drive the bulk of its revenue base.

Insider activity and ownership structure

While no major insider director dealings have been reported in the past few weeks, ownership disclosures highlight the growing role of large institutions in AbbVie’s share register, illustrated by Norges Bank’s recently reported fourth?quarter purchase of roughly 25.7 million shares worth about USD 5.87 billion, equal to around 1.45% of the company’s stock.MarketBeat as of 05/30/2026 In addition, other institutional investors such as Första AP?fonden, one of Sweden’s national pension funds, have reported increasing their stakes, with Första AP?fonden lifting its AbbVie holdings by 2.5% in the fourth quarter, according to a separate regulatory filing summary.MarketBeat as of 05/30/2026

These disclosures confirm that a significant portion of AbbVie’s free float is concentrated in the hands of global asset managers and sovereign institutions, which can influence liquidity and voting outcomes at shareholder meetings but also provide a stable base of long?horizon capital that may help support ongoing investment in its research and development pipeline.

Conclusion

The combination of a new FDA approval for DECNUPAZ in an ultra?rare blood cancer and the emergence of Norges Bank as a top?20 shareholder provides AbbVie with both a fresh oncology milestone in its home U.S. market and visible endorsement from a major global institution. Together with steady interest from other pension funds and asset managers, these developments highlight how regulatory progress and a broad institutional ownership base are shaping the narrative around AbbVie’s pipeline?driven growth profile.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.